$RPRX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REPROS THERAPEUTICS INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in REPROS THERAPEUTICS INC.. Get notifications about new insider transactions in REPROS THERAPEUTICS INC. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 27 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 6.32 | 17,309 | 109,393 | 4,201,719 | 4.2 M to 4.2 M (+0.41 %) |
| Oct 21 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 6.42 | 30,000 | 192,600 | 4,184,410 | 4.2 M to 4.2 M (+0.72 %) |
| Oct 21 2008 | RPRX | REPROS THERAPEUTIC ... | Lappe Mark | Director | Buy | P | 6.42 | 30,000 | 192,600 | 4,184,410 | 4.2 M to 4.2 M (+0.72 %) |
| Oct 07 2008 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 7.18 | 400 | 2,872 | 115,281 | 114.9 K to 115.3 K (+0.35 %) |
| Oct 07 2008 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 7.14 | 4,000 | 28,560 | 114,881 | 110.9 K to 114.9 K (+3.61 %) |
| Oct 15 2008 | RPRX | REPROS THERAPEUTIC ... | Masterson Nola E | Director | Buy | P | 7.00 | 400 | 2,800 | 1,000 | 600 to 1,000 (+66.67 %) |
| Oct 14 2008 | RPRX | REPROS THERAPEUTIC ... | Lappe Mark | Director | Buy | P | 6.82 | 15,000 | 102,300 | 4,154,410 | 4.1 M to 4.2 M (+0.36 %) |
| Oct 14 2008 | RPRX | REPROS THERAPEUTIC ... | Lappe Mark | Director | Buy | P | 6.23 | 15,300 | 95,319 | 4,139,410 | 4.1 M to 4.1 M (+0.37 %) |
| Oct 14 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 6.82 | 15,000 | 102,300 | 4,154,410 | 4.1 M to 4.2 M (+0.36 %) |
| Oct 14 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 6.23 | 15,300 | 95,319 | 4,139,410 | 4.1 M to 4.1 M (+0.37 %) |
| Oct 07 2008 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Buy | P | 6.96 | 800 | 5,568 | 41,017 | 40.2 K to 41 K (+1.99 %) |
| Oct 07 2008 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Buy | P | 7.22 | 2,000 | 14,440 | 40,217 | 38.2 K to 40.2 K (+5.23 %) |
| Oct 06 2008 | RPRX | REPROS THERAPEUTIC ... | REED JOHN C | Director | Buy | P | 6.50 | 25,000 | 162,500 | 25,000 | 0 to 25 K |
| Oct 06 2008 | RPRX | REPROS THERAPEUTIC ... | Lappe Mark | Director | Buy | P | 6.50 | 1,846,154 | 12,000,001 | 4,124,110 | 2.3 M to 4.1 M (+81.04 %) |
| Oct 06 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 6.50 | 1,846,154 | 12,000,001 | 4,124,110 | 2.3 M to 4.1 M (+81.04 %) |
| Oct 01 2008 | RPRX | REPROS THERAPEUTIC ... | Lappe Mark | Director | Option Exercise | A | 6.08 | 40,000 | 243,200 | 40,000 | |
| Oct 01 2008 | RPRX | REPROS THERAPEUTIC ... | REED JOHN C | Director | Option Exercise | A | 0.00 | 40,000 | 0 | 40,000 | |
| Jul 03 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Sell | S | 9.55 | 55,800 | 532,890 | 2,277,956 | 2.3 M to 2.3 M (-2.39 %) |
| Jul 03 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Sell | S | 9.82 | 10,000 | 98,200 | 2,333,756 | 2.3 M to 2.3 M (-0.43 %) |
| Jul 03 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Sell | S | 9.58 | 60,000 | 574,800 | 2,343,756 | 2.4 M to 2.3 M (-2.50 %) |
| Jul 03 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Sell | S | 9.61 | 50,000 | 480,500 | 2,403,756 | 2.5 M to 2.4 M (-2.04 %) |
| Jul 03 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Sell | S | 8.94 | 34,000 | 303,960 | 2,453,756 | 2.5 M to 2.5 M (-1.37 %) |
| Jul 03 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Sell | S | 8.90 | 10,600 | 94,340 | 2,487,756 | 2.5 M to 2.5 M (-0.42 %) |
| Jul 03 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Sell | S | 8.54 | 55,357 | 472,749 | 2,498,356 | 2.6 M to 2.5 M (-2.17 %) |
| Jul 03 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Sell | S | 8.59 | 26,300 | 225,917 | 2,553,713 | 2.6 M to 2.6 M (-1.02 %) |
| Jun 10 2008 | RPRX | REPROS THERAPEUTIC ... | Wiehle Ronald | Vice President, R&D | Option Exercise | A | 10.65 | 20,000 | 213,000 | 20,000 | |
| May 23 2008 | RPRX | REPROS THERAPEUTIC ... | Harder Jeffrey R | Director | Buy | P | 9.14 | 1,000 | 9,140 | 8,499 | 7.5 K to 8.5 K (+13.34 %) |
| Jun 10 2008 | RPRX | REPROS THERAPEUTIC ... | van As Andre MD, PhD | Chief Medical Offic ... | Option Exercise | A | 10.65 | 30,000 | 319,500 | 30,000 | |
| May 21 2008 | RPRX | REPROS THERAPEUTIC ... | FOURCROY JEAN L MD PHD MPH | Director | Buy | P | 9.34 | 600 | 5,603 | 600 | 0 to 600 |
| May 15 2008 | RPRX | REPROS THERAPEUTIC ... | Harder Jeffrey R | Director | Option Exercise | A | 8.72 | 5,000 | 43,600 | 5,000 | |
| May 15 2008 | RPRX | REPROS THERAPEUTIC ... | CAIN DANIEL F | Director | Option Exercise | A | 8.72 | 5,000 | 43,600 | 5,000 | |
| May 15 2008 | RPRX | REPROS THERAPEUTIC ... | FOURCROY JEAN L MD PHD MPH | Director | Option Exercise | A | 8.72 | 5,000 | 43,600 | 5,000 | |
| May 15 2008 | RPRX | REPROS THERAPEUTIC ... | Poorvin David | Director | Option Exercise | A | 8.72 | 5,000 | 43,600 | 5,000 | |
| May 15 2008 | RPRX | REPROS THERAPEUTIC ... | Masterson Nola E | Director | Option Exercise | A | 8.72 | 5,000 | 43,600 | 5,000 | |
| Apr 22 2008 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Buy | P | 8.77 | 500 | 4,385 | 38,217 | 37.7 K to 38.2 K (+1.33 %) |
| Apr 17 2008 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 8.86 | 1,500 | 13,291 | 110,881 | 109.4 K to 110.9 K (+1.37 %) |
| Apr 16 2008 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Buy | P | 8.68 | 1,000 | 8,679 | 37,717 | 36.7 K to 37.7 K (+2.72 %) |
| Apr 16 2008 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Buy | P | 8.83 | 1,000 | 8,826 | 36,717 | 35.7 K to 36.7 K (+2.80 %) |
| Apr 15 2008 | RPRX | REPROS THERAPEUTIC ... | Harder Jeffrey R | Director | Buy | P | 8.51 | 900 | 7,659 | 7,499 | 6.6 K to 7.5 K (+13.64 %) |
| Apr 15 2008 | RPRX | REPROS THERAPEUTIC ... | Harder Jeffrey R | Director | Buy | P | 8.49 | 100 | 849 | 6,599 | 6.5 K to 6.6 K (+1.54 %) |
| Apr 09 2008 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 9.00 | 1,000 | 8,996 | 109,381 | 108.4 K to 109.4 K (+0.92 %) |
| Mar 13 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 8.50 | 50,000 | 425,000 | 2,580,013 | 2.5 M to 2.6 M (+1.98 %) |
| Mar 11 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 8.46 | 40,000 | 338,400 | 2,530,013 | 2.5 M to 2.5 M (+1.61 %) |
| Mar 11 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 8.63 | 34,500 | 297,735 | 2,530,013 | 2.5 M to 2.5 M (+1.38 %) |
| Mar 03 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 8.27 | 30,000 | 248,100 | 2,455,513 | 2.4 M to 2.5 M (+1.24 %) |
| Mar 03 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 8.35 | 20,000 | 167,000 | 2,425,513 | 2.4 M to 2.4 M (+0.83 %) |
| Mar 03 2008 | RPRX | REPROS THERAPEUTIC ... | Harder Jeffrey R | Director | Buy | P | 8.54 | 500 | 4,271 | 6,499 | 6 K to 6.5 K (+8.33 %) |
| Feb 26 2008 | RPRX | REPROS THERAPEUTIC ... | Harder Jeffrey R | Director | Buy | P | 8.80 | 500 | 4,398 | 5,999 | 5.5 K to 6 K (+9.09 %) |
| Feb 06 2008 | RPRX | REPROS THERAPEUTIC ... | Masterson Nola E | Director | Buy | P | 8.60 | 500 | 4,300 | 600 | 100 to 600 (+500.00 %) |
| Jan 28 2008 | RPRX | REPROS THERAPEUTIC ... | Harder Jeffrey R | Director | Buy | P | 8.92 | 200 | 1,784 | 5,499 | 5.3 K to 5.5 K (+3.77 %) |
| Jan 28 2008 | RPRX | REPROS THERAPEUTIC ... | Harder Jeffrey R | Director | Buy | P | 8.89 | 800 | 7,112 | 5,299 | 4.5 K to 5.3 K (+17.78 %) |
| Jan 08 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 9.08 | 19,500 | 177,060 | 2,405,513 | 2.4 M to 2.4 M (+0.82 %) |
| Jan 08 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 8.96 | 15,000 | 134,400 | 2,386,913 | 2.4 M to 2.4 M (+0.63 %) |
| Jan 02 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 9.43 | 54,100 | 510,163 | 2,371,013 | 2.3 M to 2.4 M (+2.34 %) |
| Jan 02 2008 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 9.32 | 70,000 | 652,400 | 2,316,913 | 2.2 M to 2.3 M (+3.12 %) |
| Jan 02 2008 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 9.36 | 1,000 | 9,360 | 108,381 | 107.4 K to 108.4 K (+0.93 %) |
| Dec 21 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 9.38 | 40,000 | 375,200 | 2,246,913 | 2.2 M to 2.2 M (+1.81 %) |
| Dec 21 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 9.49 | 60,000 | 569,400 | 2,206,913 | 2.1 M to 2.2 M (+2.79 %) |
| Nov 02 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 12.69 | 17,000 | 215,713 | 0 | -17,000 to 0 (-100.00 %) |
| Nov 02 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 12.55 | 25,000 | 313,725 | 0 | -25,000 to 0 (-100.00 %) |
| Nov 02 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 12.53 | 25,000 | 313,350 | 0 | -25,000 to 0 (-100.00 %) |
| Nov 02 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 12.18 | 25,000 | 304,550 | 0 | -25,000 to 0 (-100.00 %) |
| Nov 02 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 12.34 | 40,500 | 499,608 | 0 | -40,500 to 0 (-100.00 %) |
| Nov 02 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 12.48 | 21,900 | 273,334 | 0 | -21,900 to 0 (-100.00 %) |
| Nov 02 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 12.44 | 62,600 | 778,744 | 0 | -62,600 to 0 (-100.00 %) |
| Dec 18 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 9.78 | 120,000 | 1,173,600 | 2,061,313 | 1.9 M to 2.1 M (+6.18 %) |
| Dec 18 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 8.70 | 40,100 | 348,870 | 1,941,313 | 1.9 M to 1.9 M (+2.11 %) |
| Dec 20 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 9.84 | 43,500 | 428,040 | 0 | -43,500 to 0 (-100.00 %) |
| Dec 20 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 9.79 | 42,100 | 412,159 | 0 | -42,100 to 0 (-100.00 %) |
| Dec 07 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 7.96 | 60,000 | 477,600 | 1,901,213 | 1.8 M to 1.9 M (+3.26 %) |
| Dec 07 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 8.18 | 39,300 | 321,474 | 1,841,213 | 1.8 M to 1.8 M (+2.18 %) |
| Dec 05 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 8.35 | 50,000 | 417,500 | 1,801,913 | 1.8 M to 1.8 M (+2.85 %) |
| Dec 05 2007 | RPRX | REPROS THERAPEUTIC ... | Efficacy Capital, Ltd. | 10% Owner | Buy | P | 7.86 | 71,500 | 561,990 | 1,751,913 | 1.7 M to 1.8 M (+4.25 %) |
| Oct 26 2007 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 12.66 | 1,000 | 12,660 | 107,381 | 106.4 K to 107.4 K (+0.94 %) |
| May 18 2007 | RPRX | REPROS THERAPEUTIC ... | CAIN DANIEL F | Director | Option Exercise | A | 12.37 | 5,000 | 61,850 | 5,000 | |
| May 18 2007 | RPRX | REPROS THERAPEUTIC ... | FOURCROY JEAN L MD PHD MPH | Director | Option Exercise | A | 12.37 | 5,000 | 61,850 | 5,000 | |
| May 18 2007 | RPRX | REPROS THERAPEUTIC ... | Harder Jeffrey R | Director | Option Exercise | A | 12.37 | 5,000 | 61,850 | 5,000 | |
| May 18 2007 | RPRX | REPROS THERAPEUTIC ... | Masterson Nola E | Director | Option Exercise | A | 12.37 | 5,000 | 61,850 | 5,000 | |
| May 18 2007 | RPRX | REPROS THERAPEUTIC ... | Poorvin David | Director | Option Exercise | A | 12.37 | 5,000 | 61,850 | 5,000 | |
| Jan 11 2007 | RPRX | REPROS THERAPEUTIC ... | van As Andre MD, PhD | Chief Medical Offic ... | Buy | P | 12.20 | 2,000 | 24,400 | 10,000 | 8 K to 10 K (+25.00 %) |
| Jan 08 2007 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Option Exercise | A | 12.26 | 50,000 | 613,000 | 50,000 | |
| Jan 08 2007 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Option Exercise | A | 12.26 | 20,000 | 245,200 | 20,000 | |
| Jan 05 2007 | RPRX | REPROS THERAPEUTIC ... | Wiehle Ronald | Vice President, R&D | Option Exercise | A | 12.24 | 20,000 | 244,800 | 20,000 | |
| Dec 27 2006 | RPRX | REPROS THERAPEUTIC ... | van As Andre MD, PhD | Chief Medical Offic ... | Buy | P | 11.85 | 410 | 4,859 | 410 | 0 to 410 |
| Dec 21 2006 | RPRX | REPROS THERAPEUTIC ... | van As Andre MD, PhD | Chief Medical Offic ... | Option Exercise | A | 6.17 | 50,000 | 308,500 | 50,000 | |
| Dec 21 2006 | RPRX | REPROS THERAPEUTIC ... | van As Andre MD, PhD | Chief Medical Offic ... | Buy | P | 7.08 | 2,000 | 14,160 | 8,000 | 6 K to 8 K (+33.33 %) |
| Dec 04 2006 | RPRX | REPROS THERAPEUTIC ... | Harder Jeffrey R | Director | Buy | P | 5.90 | 1,000 | 5,900 | 1,000 | 0 to 1,000 |
| Dec 04 2006 | RPRX | REPROS THERAPEUTIC ... | Harder Jeffrey R | Director | Buy | P | 5.87 | 1,000 | 5,870 | 4,499 | 3.5 K to 4.5 K (+28.58 %) |
| Dec 01 2006 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 5.90 | 1,500 | 8,850 | 106,381 | 104.9 K to 106.4 K (+1.43 %) |
| Nov 29 2006 | RPRX | REPROS THERAPEUTIC ... | Masterson Nola E | Director | Buy | P | 5.59 | 100 | 559 | 100 | 0 to 100 |
| Dec 01 2006 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Buy | P | 5.90 | 1,070 | 6,313 | 35,717 | 34.6 K to 35.7 K (+3.09 %) |
| Nov 28 2006 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Buy | P | 5.72 | 1,000 | 5,720 | 34,647 | 33.6 K to 34.6 K (+2.97 %) |
| Nov 14 2006 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 5.71 | 2,000 | 11,417 | 104,881 | 102.9 K to 104.9 K (+1.94 %) |
| Nov 02 2006 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Buy | P | 7.95 | 925 | 7,349 | 33,647 | 32.7 K to 33.6 K (+2.83 %) |
| Oct 31 2006 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 8.18 | 2,000 | 16,357 | 102,881 | 100.9 K to 102.9 K (+1.98 %) |
| Jul 27 2006 | RPRX | REPROS THERAPEUTIC ... | CAIN DANIEL F | Director | Buy | P | 8.34 | 2,000 | 16,680 | 2,000 | 0 to 2 K |
| Jul 07 2006 | RPRX | REPROS THERAPEUTIC ... | Harder Jeffrey R | Director | Buy | P | 7.95 | 1,000 | 7,950 | 3,499 | 2.5 K to 3.5 K (+40.02 %) |
| May 05 2006 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 10.99 | 1,000 | 10,990 | 100,881 | 99.9 K to 100.9 K (+1.00 %) |
| May 04 2006 | RPRX | REPROS THERAPEUTIC ... | Harder Jeffrey R | Director | Option Exercise | A | 12.70 | 5,000 | 63,500 | 5,000 | |
| May 04 2006 | RPRX | REPROS THERAPEUTIC ... | FOURCROY JEAN L MD PHD MPH | Director | Option Exercise | A | 12.70 | 5,000 | 63,500 | 5,000 | |
| May 04 2006 | RPRX | REPROS THERAPEUTIC ... | CAIN DANIEL F | Director | Option Exercise | A | 12.70 | 5,000 | 63,500 | 5,000 | |
| May 04 2006 | RPRX | REPROS THERAPEUTIC ... | Masterson Nola E | Director | Option Exercise | A | 12.70 | 5,000 | 63,500 | 5,000 | |
| May 04 2006 | RPRX | REPROS THERAPEUTIC ... | Poorvin David | Director | Option Exercise | A | 12.70 | 5,000 | 63,500 | 5,000 | |
| Jan 03 2006 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 4.98 | 700 | 3,486 | 99,881 | 99.2 K to 99.9 K (+0.71 %) |
| Jun 23 2005 | RPRX | REPROS THERAPEUTIC ... | FOURCROY JEAN L MD PHD MPH | Director | Option Exercise | A | 3.71 | 5,000 | 18,550 | 5,000 | |
| Jun 23 2005 | RPRX | REPROS THERAPEUTIC ... | CAIN DANIEL F | Director | Option Exercise | A | 3.71 | 5,000 | 18,550 | 5,000 | |
| Jun 23 2005 | RPRX | REPROS THERAPEUTIC ... | Masterson Nola E | Director | Option Exercise | A | 3.71 | 5,000 | 18,550 | 5,000 | |
| Jun 23 2005 | RPRX | REPROS THERAPEUTIC ... | Poorvin David | Director | Option Exercise | A | 3.71 | 5,000 | 18,550 | 5,000 | |
| Jun 23 2005 | RPRX | REPROS THERAPEUTIC ... | Harder Jeffrey R | Director | Option Exercise | A | 3.71 | 40,000 | 148,400 | 40,000 | |
| Apr 06 2005 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 2.90 | 2,000 | 5,800 | 99,181 | 97.2 K to 99.2 K (+2.06 %) |
| Apr 06 2005 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 2.90 | 2,000 | 5,800 | 99,181 | 97.2 K to 99.2 K (+2.06 %) |
| Apr 05 2005 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Buy | P | 2.98 | 425 | 1,267 | 32,722 | 32.3 K to 32.7 K (+1.32 %) |
| Mar 22 2005 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Buy | P | 3.10 | 2,500 | 7,750 | 32,297 | 29.8 K to 32.3 K (+8.39 %) |
| Mar 10 2005 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 3.24 | 1,000 | 3,241 | 97,181 | 96.2 K to 97.2 K (+1.04 %) |
| Mar 10 2005 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Buy | P | 3.24 | 2,000 | 6,488 | 96,181 | 94.2 K to 96.2 K (+2.12 %) |
| Oct 08 2004 | RPRX | REPROS THERAPEUTIC ... | Poorvin David | Director | Option Exercise | A | 3.60 | 40,000 | 144,000 | 40,000 | |
| Oct 08 2004 | RPRX | REPROS THERAPEUTIC ... | Masterson Nola E | Director | Option Exercise | A | 3.60 | 40,000 | 144,000 | 40,000 | |
| Oct 01 2004 | RPRX | REPROS THERAPEUTIC ... | LAVOTHA ZSOLT E | Director | Option Exercise | A | 3.60 | 5,000 | 18,000 | 5,000 | |
| Oct 01 2004 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Option Exercise | A | 2.72 | 106,213 | 288,899 | 106,213 | |
| Oct 01 2004 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Option Exercise | A | 2.72 | 20,925 | 56,916 | 20,925 | |
| Oct 01 2004 | RPRX | REPROS THERAPEUTIC ... | FOURCROY JEAN L MD PHD MPH | Director | Option Exercise | A | 3.60 | 5,000 | 18,000 | 5,000 | |
| Oct 01 2004 | RPRX | REPROS THERAPEUTIC ... | CAIN DANIEL F | Director | Option Exercise | A | 3.60 | 5,000 | 18,000 | 5,000 | |
| Oct 01 2004 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Option Exercise | A | 2.72 | 157,568 | 428,585 | 157,568 | |
| Oct 01 2004 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President and CEO | Option Exercise | A | 2.72 | 58,561 | 159,286 | 58,561 | |
| Aug 18 2004 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President & CEO | Buy | P | 2.97 | 2,000 | 5,940 | 94,181 | 92.2 K to 94.2 K (+2.17 %) |
| Mar 31 2004 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Option Exercise | A | 2.72 | 38,245 | 104,026 | 38,245 | |
| Mar 31 2004 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President & CEO | Option Exercise | A | 2.72 | 56,737 | 154,325 | 56,737 | |
| Jan 26 2004 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President & CEO | Option Exercise | A | 2.40 | 58,561 | 140,546 | 58,561 | |
| Jan 26 2004 | RPRX | REPROS THERAPEUTIC ... | PODOLSKI JOSEPH | President & CEO | Option Exercise | A | 2.40 | 214,305 | 514,332 | 214,305 | |
| Jan 26 2004 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Option Exercise | A | 2.40 | 20,925 | 50,220 | 20,925 | |
| Jan 26 2004 | RPRX | REPROS THERAPEUTIC ... | PLOTH LOUIS JR | VP & Chief Financia ... | Option Exercise | A | 2.40 | 144,458 | 346,699 | 144,458 |